Annexon (ANNX) Income towards Parent Company (2019 - 2026)
Annexon (ANNX) posted quarterly Income towards Parent Company of -$78.1 million for Q1 2026, down 9.25% year-over-year from -$86.0 million in Q1 2025, and down 15.75% quarter-over-quarter from -$67.4 million in Q4 2025.
Annexon (ANNX) Income towards Parent Company (2019 - 2026) Analysis & Trends
Annexon's Income towards Parent Company history runs 8 years deep, the most recent figure standing at -$78.1 million for Q1 2026.
- In Q1 2026, Income towards Parent Company fell 9.25% year-over-year to -$78.1 million; the TTM figure through Mar 2026 stood at -$268.0 million (up 4.7% YoY), while the FY2025 annual figure was -$441.3 million, down 31.76% from the prior year.
- Income towards Parent Company for Q1 2026 stood at -$78.1 million, down from -$67.4 million in the prior quarter.
- The five-year high for Income towards Parent Company was -$40.0 million in Q4 2022, with the low at -$160.9 million in Q4 2023.
- The 5-year median for Income towards Parent Company is -$71.5 million (2025), against an average of -$74.2 million.
- The sharpest annual moves came in 2023 and 2024: Income towards Parent Company sank 302.25% in 2023, then jumped 64.82% in 2024.
- Annexon's Income towards Parent Company stood at -$40.0 million in 2022, then tumbled by 302.25% to -$160.9 million in 2023, then surged by 64.82% to -$56.6 million in 2024, then fell by 19.16% to -$67.4 million in 2025, then retreated by 15.75% to -$78.1 million in 2026.
- Business Quant data shows ANNX's Income towards Parent Company at -$78.1 million in Q1 2026, -$67.4 million in Q4 2025, and -$62.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Annexon | 1.00 Bn | 1.00 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -87.89 Mn |
| Mar 31, 2026 | -78.07 Mn |
| Dec 31, 2025 | -67.45 Mn |
| Sep 30, 2025 | -62.62 Mn |
| Jun 30, 2025 | -59.91 Mn |
| Mar 31, 2025 | -71.46 Mn |
| Dec 31, 2024 | -56.60 Mn |
| Sep 30, 2024 | -78.85 Mn |
| Jun 30, 2024 | -74.36 Mn |
| Mar 31, 2024 | -70.62 Mn |
| Dec 31, 2023 | -160.89 Mn |
| Sep 30, 2023 | -78.77 Mn |
| Jun 30, 2023 | -82.85 Mn |
| Mar 31, 2023 | -54.96 Mn |
| Dec 31, 2022 | -40.00 Mn |
| Sep 30, 2022 | -84.77 Mn |
| Jun 30, 2022 | -53.21 Mn |
| Mar 31, 2022 | -86.25 Mn |
| Dec 31, 2021 | -106.71 Mn |
| Sep 30, 2021 | -35.60 Mn |